Polygenic risk scores used for Parkinson's Disease treatment and prognosis
Abstract
Parkinson’s disease is the second most common neurodegenerative disorder, characterized by progressive degeneration of dopamine-producing neurons in the brain. While genetic factors contribute to disease risk, genetic testing is not routinely offered in clinical settings, limiting its potential to inform prognosis, and treatment response. This infographic addresses the gap in clinical application of genetic testing by highlighting the role of polygenic risk scores (PRS) as predictive tools. PRS aggregate the effects of genetic variants to improve risk assessment and clinical decision-making. Advancing research and drug development, PRS have the potential to enhance public health strategies and improve patient outcomes.
Primary Faculty Mentor Name
Melissa Pespeni
Status
Undergraduate
Student College
College of Arts and Sciences
Program/Major
Neuroscience
Primary Research Category
Life Sciences
Polygenic risk scores used for Parkinson's Disease treatment and prognosis
Parkinson’s disease is the second most common neurodegenerative disorder, characterized by progressive degeneration of dopamine-producing neurons in the brain. While genetic factors contribute to disease risk, genetic testing is not routinely offered in clinical settings, limiting its potential to inform prognosis, and treatment response. This infographic addresses the gap in clinical application of genetic testing by highlighting the role of polygenic risk scores (PRS) as predictive tools. PRS aggregate the effects of genetic variants to improve risk assessment and clinical decision-making. Advancing research and drug development, PRS have the potential to enhance public health strategies and improve patient outcomes.
